Posted: Jun 08, 2021 12:01 AM
The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
June marks Alzheimer’s and Brain Awareness Month. In the United States, nearly six million Americans are living with Alzheimer’s disease. Globally, more than 50 million people are currently afflicted with Alzheimer’s.
Alzheimer’s is a relentless disease that impairs memory and other central mental functions. Thankfully, there is finally a bit of hope that we could be closer to a cure for Alzheimer’s by way of a newly approved experimental drug.
The Food and Drug Administration (FDA) recently approved Biogen’sAduhelm(aducanumab), an experimental drug used to treat Alzheimer’s disease. This is the first Alzheimer’s treatment that has come to market since 2003.
Under the FDA’s Accelerated Approval Program (AAP), this treatment has been brought to market sooner than the traditional drug approval process would have ever allowed. In short, AAP applies to life-threatening or serious conditions. The drug manufacturers are still required to prove efficacy and show the drug provides clinical benefit. Furthermore, under AAP, the FDA maintains